Troy– Author –
-
NIH-Funded Team Discovers Miniaturized Al3Cas12f CRISPR Enzyme, Dramatically Enhancing In Vivo Precision Delivery and Solving a Major Gene Therapy Bottleneck
National Institutes of Health (NIH) (News Release) USA Overview An NIH-funded research team has discovered an improved CRISPR gene-editing system enabling precise in vivo gene delivery. This breakthrough involves identifying the naturall... -
USC Viterbi Engineers Develop ‘SHIFTERS’ Strategy to Enhance CAR T-Cell Efficacy Against Solid Tumors Using Hypoxia and Focused Ultrasound for Inducible CD19 Expression
Bioengineer.org USA Overview Researchers at the USC Viterbi School of Engineering have developed 'SHIFTERS,' a novel strategy to boost CAR T-cell efficacy against solid tumors. This innovative approach leverages tumor hypoxia and focused... -
MD Anderson Researchers Identify Immature NK Cell Subpopulation in Donor Umbilical Cord Blood That Compromises CAR-NK Cell Therapy Antitumor Activity
Mirage News USA Overview Researchers at MD Anderson have discovered that a specific subpopulation of immature natural killer (NK) cells found in donor umbilical cord blood can diminish the antitumor activity of chimeric antigen receptor ... -
Sana Biotechnology Advances Hypoimmune iPSC-Derived SC451 for Type 1 Diabetes and In Vivo CAR T SG293 for Non-Hodgkin Lymphoma Towards Clinical Entry, Bolstered by NEJM Publication of Long-Term Pancreatic Islet Data
Sana Biotechnology, Inc. (Press Release) USA Overview Sana Biotechnology reported significant progress towards initiating clinical trials for SC451, an iPSC-derived pancreatic islet cell therapy for Type 1 diabetes, and SG293, an in vivo... -
Fate Therapeutics Initiates Phase 2 Trial for iPSC-Derived Off-the-Shelf CAR T-Cell Therapy FT819 in Lupus Nephritis, Gains FDA IND Approval for Autoimmune FT839
Fate Therapeutics, Inc. (Press Release) USA Overview Fate Therapeutics reported significant advancements in its iPSC-derived off-the-shelf CAR T-cell immunotherapy pipeline, with the first patient dosed in the Phase 2 RECLAIM-LN study of... -
Intellia Therapeutics Advances CRISPR Gene Editing: Lonvo-z Achieves Phase 3 Success for HAE, Targeting Mid-2027 U.S. Launch; Nex-z Phase 3 Enrollment Resumes for ATTR
Intellia Therapeutics, Inc. (Press Release) USA Overview Intellia Therapeutics reported positive Phase 3 results for lonvo-z in hereditary angioedema (HAE), with a Biologics License Application (BLA) submission to the FDA planned for H2 ... -
FDA Advances AI Medical Device Regulation Clarity Amidst “AI Premium” Driving Investment, Challenges Remain for Generative AI
Facebook (STAT News) USA Overview The MedTech industry experienced a strategic reset, with AI-enabled companies commanding a 19% premium on average deal size in 2025, and US startups raising $14.2 billion. While the FDA is updating guida... -
UBS and FactSet Invest in Finster AI, HSBC in Model ML, Accelerating AI Adoption in Finance
TechCrunch USA Overview UBS Investment Bank and FactSet have invested in Finster AI, an AI intelligence platform, signaling interest in technologies that support the evolution of investment banking workflows. HSBC Asset Management also i... -
CrystalO Biopharma Signs Collaboration and Licensing Deal with Almirall for AI-Driven Skin Disease Drug Discovery, Valued Up to €254.5 Million
Insight, China's Pharmaceutical Industry China Overview CrystalO Biopharma has signed a collaboration and licensing agreement with Almirall, a global biopharmaceutical company, to develop innovative drug candidates for skin diseases. The... -
Challenges in Rapid AI Tool Development and Deployment in Clinics: Data Privacy, Algorithmic Bias, and Regulatory Delays
Facebook (STAT News) USA Overview The rapid development and deployment of clinical AI tools raise significant challenges and ethical concerns, including data privacy risks, algorithmic bias, and the 'black box' nature of many AI models. ...
